Senores Pharmaceuticals Q1FY26: 71% Revenue Surge & The Strategic Moves Fueling Its Super Growth

Senores Pharmaceuticals’ Q1FY26 results are turning heads with impressive growth across key …

Aug 11, 2025 01:27

Senores Pharma's Havix Unit: USFDA Inspection Concludes, Stock at ₹644 📉

Senores Pharmaceuticals’ US subsidiary, Havix, completed its USFDA inspection with 3 minor …

Jul 28, 2025 15:54